Fleishaker J C, Rossi S S, Smith R B, Welshman I R, Daei F, Angellotti M A, Hofmann A F
Clinical Pharmacokinetics Unit, Upjohn Company, Kalamazoo, MI.
Aliment Pharmacol Ther. 1990 Dec;4(6):623-33. doi: 10.1111/j.1365-2036.1990.tb00510.x.
A dose-response study was performed with three doses of colestipol, using postprandial serum bile acid levels to assess bile acid sequestering activity in 40 volunteers with asymptomatic hyperlipidaemia. Subjects who entered the study had total serum cholesterol concentrations greater than 220 mg/dl and triglyceride concentrations less than 200 mg/dl. They were randomly assigned to one of four parallel treatment groups: (a) placebo b.d., (b) colestipol (as Colestid hydrochloride granules) 2.5 g b.d., (c) colestipol 5 g b.d., and (d) colestipol 7.5 g b.d. Subjects were maintained on a constant repeating solid diet throughout the 6-day study period, and colestipol was ingested 30 min before breakfast and dinner. No drug was administered on Days 1-3; baseline (pre-treatment) serum bile acid concentration profiles were determined on Day 3. The above treatments were given on Days 4-6, and total serum bile acid concentrations were determined at 30- or 60-min intervals for 10 h on Days 4 and 6. Serum bile acids were measured using a bioluminescence procedure which enzymically measures total 3 alpha hydroxy bile acids. Serum bile acid concentrations were significantly decreased from the pretreatment period by 5.0 and 7.5 g/day as compared to 2.5 g/day or placebo. Differences from the pre-treatment period in the area under the serum bile acid time curve revealed the same trends in the data as analysis of percentage difference (Day 6 vs pre-treatment period) in serum bile acid concentrations. These results indicate that postprandial serum bile acid concentrations are influenced by colestipol in a dose-related manner, with doses of 5 and 7.5 g b.d. having a significantly greater effect than 2.5 g b.d. The dose of 7.5 g b.d. had an identical effect on serum bile acid patterns as a dose of 5.0 g t.d.s., which was previously reported. Our findings also show that changes in serum bile acid concentrations may be used to follow the immediate effects of bile acid sequestration in hypercholes terolaemic subjects, and that the bioluminescence enzyme technique is sufficiently sensitive to detect such changes.
对40名无症状高脂血症志愿者进行了一项使用三种剂量考来烯胺的剂量反应研究,采用餐后血清胆汁酸水平评估胆汁酸螯合活性。进入该研究的受试者血清总胆固醇浓度大于220mg/dl,甘油三酯浓度小于200mg/dl。他们被随机分配到四个平行治疗组之一:(a) 每日两次安慰剂,(b) 考来烯胺(以盐酸考来烯胺颗粒形式)每日两次2.5g,(c) 考来烯胺每日两次5g,以及(d) 考来烯胺每日两次7.5g。在整个6天的研究期间,受试者维持恒定的重复固体饮食,考来烯胺在早餐和晚餐前30分钟服用。第1 - 3天不给药;在第3天测定基线(治疗前)血清胆汁酸浓度曲线。上述治疗在第4 - 6天进行,在第4天和第6天每隔30或60分钟测定10小时的血清总胆汁酸浓度。使用生物发光法测量血清胆汁酸,该方法通过酶法测量总3α - 羟基胆汁酸。与每日2.5g或安慰剂相比,每日5.0g和7.5g考来烯胺使血清胆汁酸浓度较治疗前期显著降低。血清胆汁酸时间曲线下面积与治疗前期相比的差异显示出与血清胆汁酸浓度百分比差异分析(第6天与治疗前期)相同的数据趋势。这些结果表明,餐后血清胆汁酸浓度受考来烯胺的影响呈剂量相关方式,每日两次5g和7.5g的剂量比每日两次2.5g的效果显著更大。每日两次7.5g的剂量对血清胆汁酸模式的影响与先前报道的每日三次5.0g的剂量相同。我们的研究结果还表明,血清胆汁酸浓度的变化可用于追踪高胆固醇血症受试者胆汁酸螯合的即时效果,并且生物发光酶技术足够灵敏以检测此类变化。